within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DE51_CefepimeAndBetaLactamaseInhibitor;

model CefepimeAndBetaLactamaseInhibitor
  extends Pharmacolibrary.Drugs.ATC.J.J01DE51;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J01DE51</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cefepime is a fourth-generation cephalosporin antibiotic with broad-spectrum activity against Gram-positive and Gram-negative bacteria. It is often combined with a beta-lactamase inhibitor (such as tazobactam or zidebactam) to extend its activity against beta-lactamase-producing bacteria. These combinations are typically used in treatment of complicated urinary tract infections, hospital-acquired pneumonia, and other serious infections. As of now, cefepime-beta-lactamase inhibitor combinations (ATC J01DE51) are not widely approved as co-formulations, and clinical use may be limited to investigational or compassionate settings.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data available specifically for cefepime and a beta-lactamase inhibitor combination. The following parameters are estimated based on known pharmacokinetics of cefepime (adult, intravenous administration, normal renal function) and commonly used beta-lactamase inhibitors.</p><h4>References</h4><ol><li><p>Zhanel, GG, et al., &amp; Karlowsky, JA (2024). Cefepime-Taniborbactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination. <i>Drugs</i> 84(10) 1219–1250. DOI:<a href=\"https://doi.org/10.1007/s40265-024-02082-9\">10.1007/s40265-024-02082-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39214942/\">https://pubmed.ncbi.nlm.nih.gov/39214942</a></p></li><li><p>Dowell, JA, et al., &amp; Henkel, T (2021). Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor. <i>Antimicrobial agents and chemotherapy</i> 65(11) e0105321–None. DOI:<a href=\"https://doi.org/10.1128/AAC.01053-21\">10.1128/AAC.01053-21</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34370573/\">https://pubmed.ncbi.nlm.nih.gov/34370573</a></p></li><li><p>Zhanel, GG, et al., &amp; Karlowsky, JA (2019). Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. <i>Drugs</i> 79(3) 271–289. DOI:<a href=\"https://doi.org/10.1007/s40265-019-1055-2\">10.1007/s40265-019-1055-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30712199/\">https://pubmed.ncbi.nlm.nih.gov/30712199</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end CefepimeAndBetaLactamaseInhibitor;
